Intech Investment Management LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Intech Investment Management LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 52,953 shares of the company’s stock, valued at approximately $349,000.

Several other large investors have also modified their holdings of RXRX. Perceptive Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $5,769,000. Pier 88 Investment Partners LLC raised its holdings in shares of Recursion Pharmaceuticals by 442.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after buying an additional 109,210 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after buying an additional 167,302 shares during the period. Scientech Research LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $1,052,000. Finally, Ghisallo Capital Management LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $8,250,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 6.5 %

NASDAQ:RXRX opened at $7.09 on Wednesday. The stock has a 50-day simple moving average of $6.59 and a 200-day simple moving average of $7.37. The stock has a market cap of $2.03 billion, a P/E ratio of -4.63 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue was up 147.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.43) earnings per share. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RXRX has been the topic of several recent research reports. Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.25.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total value of $92,550.00. Following the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at $8,500,754.52. The trade was a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 134,235 shares of company stock valued at $895,538 in the last three months. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.